MedTrace Logo

To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors

NCT03159585 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2020-01-22

No results posted yet for this study

Summary

The main purpose of this trial is to investigate the safety and tolerability of TAEST16001（TCR Affinity Enhancing Specific T cell Therapy）in the multi-line treatment failed advanced solid tumors except non small cell lung cancer,including liver cancer,gastric cancer,esophageal cancer,bone and soft tissue tumors,breast cancer, bladder carcinoma,prostate carcinoma,thyroid cancer, ovarian cancer and so on. The patients must meet the two criteria: human leukocyte antigens (HLA)-A\*0201+ and NY-ESO-1 positive cells≥25% by immunohistochemistry.

Conditions

  • Liver Cancer Stage IV
  • Gastric Cancer Stage IV
  • Esophageal Cancer, Stage IV
  • Bone and Soft Tissue Tumors
  • Breast Cancer Stage IV
  • Bladder Carcinoma Stage IV
  • Prostate Carcinoma Stage IV
  • Thyroid Cancer Stage IV
  • Ovarian Cancer Stage IV
  • Solid Tumor

Interventions

DRUG

TAEST16001

After completion of Lymphodepleting regimen pretreatment, the subject will receive an infusion of TAEST16001

Sponsors & Collaborators

  • Xiangxue Life Science Research Center

    collaborator UNKNOWN

  • Guangdong Xiangxue Precision Medical Technology Co., Ltd.

    collaborator INDUSTRY

  • Xiangxue Pharmaceutical

    collaborator OTHER

  • Zhujiang Hospital

    lead OTHER

Principal Investigators

  • Jian Zhang · Southern Medical University, China

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-14
Primary Completion
2019-06-04
Completion
2019-06-04

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03159585 on ClinicalTrials.gov